| Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1 … S Heller, J Buse, M Fisher, S Garg, M Marre, L Merker, E Renard, ... The Lancet 379 (9825), 1489-1497, 2012 | 472 | 2012 |
| Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial HU Häring, L Merker, E Seewaldt-Becker, M Weimer, T Meinicke, ... Diabetes care 36 (11), 3396-3404, 2013 | 468 | 2013 |
| Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial HU Häring, L Merker, E Seewaldt-Becker, M Weimer, T Meinicke, ... Diabetes care 37 (6), 1650-1659, 2014 | 455 | 2014 |
| Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 … BW Bode, JB Buse, M Fisher, SK Garg, M Marre, L Merker, E Renard, ... Diabetic medicine 30 (11), 1293-1297, 2013 | 130 | 2013 |
| Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase … M Roden, L Merker, AV Christiansen, F Roux, A Salsali, G Kim, P Stella, ... Cardiovascular diabetology 14, 1-11, 2015 | 121 | 2015 |
| Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus CS Kovacs, V Seshiah, L Merker, AV Christiansen, F Roux, A Salsali, ... Clinical therapeutics 37 (8), 1773-1788. e1, 2015 | 114 | 2015 |
| Empagliflozin as add‐on to metformin in people with type 2 diabetes L Merker, HU Häring, AV Christiansen, F Roux, A Salsali, G Kim, ... Diabetic Medicine 32 (12), 1555-1567, 2015 | 97 | 2015 |
| Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes HU Haering, L Merker, AV Christiansen, F Roux, A Salsali, G Kim, ... Diabetes research and clinical practice 110 (1), 82-90, 2015 | 85 | 2015 |
| BEGIN Basal-Bolus Type 1 Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart … S Heller, J Buse, M Fisher, S Garg, M Marre, L Merker, E Renard, ... Lancet 379 (9825), 1489-1497, 2012 | 36 | 2012 |
| EMPA-REG MET Trial Investigators Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial HU Häring, L Merker, E Seewaldt-Becker, M Weimer, T Meinicke, ... Diabetes Care 37 (6), 1650-1659, 2014 | 26 | 2014 |
| EMPA-REG METSU Trial Investigators: Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo … HU Häring, L Merker, E Seewaldt-Becker, M Weimer, T Meinicke, ... Diabetes Care 36 (11), 3396-404, 2013 | 24 | 2013 |
| Higher HbA1c measurement quality standards are needed for follow-up and diagnosis: experience and analyses from Germany L Heinemann, P Kaiser, G Freckmann, D Grote-Koska, W Kerner, ... Hormone and Metabolic Research 50 (10), 728-734, 2018 | 21 | 2018 |
| HbA1c-Messung in Deutschland: Ist die Qualität ausreichend für Verlaufskontrolle und Diagnose? L Heinemann, P Kaiser, G Freckmann, D Grote-Koska, W Kerner, ... Diabetologie und Stoffwechsel 13 (01), 46-53, 2018 | 18 | 2018 |
| Empagliflozin as add-on to metformin for 24 weeks improves glycemic control in patients with type 2 diabetes (T2DM) HU Haering, L Merker, E Seewaldt-Becker, M Weimer, T Meinicke, ... Diabetes 62, A282-A282, 2013 | 17 | 2013 |
| Nephropathy in diabetes L Merker, BW Bautsch, T Ebert, M Guthoff, B Isermann Experimental and Clinical Endocrinology & Diabetes 129 (S 01), S60-S63, 2021 | 14 | 2021 |
| Empagliflozin (EMPA) Monotherapy for>= 76 Weeks in Drug-Naive Patients with Type 2 Diabetes (T2DM) MW Roden, J Weng, L Merker, AV Christiansen, F Roux, A Salsali, G Kim, ... ENDOCRINE REVIEWS 35 (3), 2014 | 11 | 2014 |
| Empagliflozin (EMPA) for>= 76 Weeks as Add-on to Metformin Plus Sulfonylurea (SU) in Patients with Type 2 Diabetes (T2DM) HU Haering, L Merker, A Vedel, CF Roux, A Salsali, G Kim, T Meinicke, ... Diabetes 63, A280-A280, 2014 | 10 | 2014 |
| Hypertonie beim Diabetes mellitus RG Bretzel, R Landgraf, HU Janka, J Mann, L Merker, T Philipp, E Ritz Diabetologie und Stoffwechsel 3 (S 2), S141-S142, 2008 | 9 | 2008 |
| Empagliflozin (EMPA) for>= 76 Weeks As Add-on to Pioglitazone with or without Metformin in Patients with Type 2 Diabetes (T2DM) CS Kovacs, V Seshiah, L Merker, AV Christiansen, F Roux, A Salsali, ... ENDOCRINE REVIEWS 35 (3), 2014 | 8 | 2014 |
| Nephropathie bei Diabetes L Merker, T Ebert, M Guthoff, B Isermann Diabetologie und Stoffwechsel 17 (S 02), S327-S331, 2022 | 7 | 2022 |
